×
Credit: PROFESSOR JOHN ZAJICEK/Science Source
Welcome to The Multiple Sclerosis Journey. Join us for a multimedia exploration of where MS treatment and research stands, what the future of care may hold, and the experiences of clinicians and patients as they collaborate on the frontlines of MS care.
The Multiple Sclerosis Journey will examine new insights on the importance of early diagnosis as well as accurate identification of the four MS phenotypes and how their recognition impacts treatment selection. Join us as we examine the importance of maintaining brain health in sustaining wellness and ability among patients with MS. Experience discussions of the role of patient and physician collaboration in sustaining continuity of care and in tailoring therapy to individual patient needs and preferences.

And, importantly, view the impact of MS through the eyes of individual patients who generously tell their stories of how they build their lives around their abilities, not their disabilities.

The road to a cure for MS lies ahead. Along the way, clinicians, physicians, and patients are sharing their stories of working toward that goal at The Multiple Sclerosis Journey. We invite you to join them.

Walk with us.

Featured Articles

Cognitive reserve may help the brain resist the effects of MS on thinking

During the past few decades, research has made clear that multiple sclerosis causes not only physical disability but also cognitive problems.

MS patients report similar satisfaction with physician, nurse care

When it comes to treating patients with multiple sclerosis (MS), a new study shows that physicians and nurse practitioners (NPs) score similarly in regard to patient satisfaction.

Cost of MS medication may go unspoken in the clinic

The cost of treatment for multiple sclerosis (MS) has been the subject of GoFundMe campaigns, an investigation by members of Congress, and recent studies in Neurology and JAMA Neurology.

Infusible MS medications work best in younger patients

Infusible disease-modifying therapies for multiple sclerosis (MS) are disproportionately more effective at quelling disease activity than oral drugs in younger patients, an advantage that fades by about age 45 years, Enrique Alvarez, MD, PhD, reported at the annual congress of the European Committee for Treatment and Research in Multiple Sclerosis.

Hypogammaglobulinemia and infection risk clarified in MS patients on anti-CD20 agents

Monitoring immunoglobulin levels regularly has become an imperative in patients with multiple sclerosis (MS) on anti-CD20 agents in light of consistent findings from long-term, open-label studies of rituximab and ocrelizumab presented at the annual congress of the European Committee for Treatment and Research in Multiple Sclerosis.